Using the superior‐performing integrated haematologic‐clinical‐apCR prediction model (higher AUC = 0.766 vs. 0.757), we developed a clinically applicable nomogram to generate an immunoscore for predicting apCR following NAT in patients with cN+ breast cancer (Figure 4). This evidence concerns the gene BRD2 and breast cancer.